Suchergebnisse

Dutch universities of applied sciences (UASs) had been teaching-only institutes since their legal origin in 1960. The development of higher education (HE) in Europe in the past twenty years requires UASs to embody and become hybrid organ-isations where education and research are integrated. Ever-changing, complex society needs professionals with overarching skills, such as critical, analytical and reflective ones. The Dutch government has framed this as a generic need for research abilities in all higher education students, in addition to framing research as a pedagogy for the development of skills. The new millennium brought Dutch UASs national funding for research and the appointment of lectoren (research professors). In 2015, the Amsterdam University of Applied Sciences (AUAS) board substantiated this national incentive in a renewed university-wide strategy to integrate research in all educational programmes. The AUAS strategic programme 'Research into Education' (Dutch: Onderzoek in Onderwijs; OiO) was designed to assist in the implementation of this aim. Educational managers and lecturers were positioned as the central actors in manifesting the intended changes. Five projects were framed, spanning from hands-on, tailor-made assistance of teaching staff to the creation of national and international networks. The aims and mechanisms for change of these projects as well as their results are presented in this chapter. Although AUAS was successful in realizing a broad desire to integrate education and research, monitoring and evaluation of the process shows how little we collectively know about functional connections between research and education, especially in applied higher education. A future strategic programme needs to bring about profes-sional enhancement at all levels to maintain the already-realised awareness and desire and take the process further to effect ability, knowledge, and reinforcement (Hiatt, 2018). It is a work in progress, yet hands-on university development can become empirically founded ...

Background: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for the treatment and/or prevention of COVID-19.Methods: Due to the initial absence of preclinical models, the effect of itraconazole was explored in a clinical, proof-of-concept, open-label, single-center study, in which hospitalized COVID-19 patients were randomly assigned to standard of care with or without itraconazole. Primary outcome was the cumulative score of the clinical status until day 15 based on the 7-point ordinal scale of the World Health Organization. In parallel, itraconazole was evaluated in a newly established hamster model of acute SARS-CoV-2 infection and transmission, as soon as the model was validated.Findings: In the hamster acute infection model, itraconazole did not reduce viral load in lungs, stools or ileum, despite adequate plasma and lung drug concentrations. In the transmission model, itraconazole failed to prevent viral transmission. The clinical trial was prematurely discontinued after evaluation of the preclinical studies and because an interim analysis showed no signal for a more favorable outcome with itraconazole: mean cumulative score of the clinical status 49 vs 47, ratio of geometric means 1.01 (95% CI 0.85 to 1.19) for itraconazole vs standard of care.Interpretation: Despite in vitro activity, itraconazole was not effective in a preclinical COVID-19 hamster model. This prompted the premature termination of the proof-of-concept clinical study. (C) 2021 The Authors. Published by Elsevier B.V. ; This project has received funding from the Covid-19-Fund KU Leuven / University Hospitals Leuven, the COVID-19 call of the Research Foundation - Flanders (FWO) (grant G0G4820N), the European Union's Horizon 2020 research and innovation program (Grant 101003627, Swift COronavirus therapeutics REsponse project) and the Bill and Melinda Gates Foundation (Grant INV-00636). LLi is member of the Institute of Tropical Medicine's Outbreak Research Team which is financially supported by the Department of Economy, Science and Innovation (EWI) of the Flemish government. BV is supported by a research grant of the Frans Van de Werf Fund for Clinical Cardiovascular Research. P. Verhamme, TV, P. Vermeersch are senior clinical investigators of the FWO. We thank Johnson & Johnson for determining drug concentrations in hamster samples and for providing guidance on the dosing. We thank Lindsey Bervoets, Carolien De Keyzer, Elke Maas and Jasper Rymentants for the technical support with the animal experiments.